Michelson takes $1.2m for OCT system
This article was originally published in Clinica
Executive Summary
UK medical imaging start-up Michelson Diagnostics is set to complete development of its hand-held optical coherence technology (OCT) system for diagnosing and treating cancer, after having raised £600,000 ($1.2m) in additional funding. Some £250,000 came from Catapult Venture Managers, £50,000 from London See Capital and the rest from private investors. London-based Michelson said its OCT system allows for an "optical biopsy" by providing real-time images of sub-surface tissue without having to remove the tissue.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.